Gassian Noémie, Frontczak Alexandre, El Kaddissi Antoine, Calcagno Fabien, Almotlak Hamadi, Barkatz Johann, Mouillet Guillaume, Maurina Tristan, Stein Ulrich, Nguyen Tan Hon T, Murez Thibaut, Thiery-Vuillemin Antoine
CHU de Besançon, oncologie, 25030 Besançon cedex, France.
CHU de Besançon, urologie, 25030 Besançon cedex, France.
Bull Cancer. 2020 Jun;107(5S):S17-S23. doi: 10.1016/S0007-4551(20)30274-5.
Penile cancers are rare, the vast majority is represented by squamous cell carcinoma, with HPV virus being found in 30 to 40% of cases. At a locally advanced or metastatic stage, first-line treatment relies on platinum and taxane based polychemotherapy. The prognosis for advanced or metastatic penile cancer remains poor, with overall survival ranging from 13.9 to 17.1 months. After the first line, guidelines recommend various chemotherapy treatments or targeted anti-EGFR therapies whose results as well as the level of evidence are limited. A better understanding of the oncogenic pathways involved in penile cancer and a frequent expression of PD-L1 are the rationale for the elaboration of new strategies. This review article presents the data, guidelines and ongoing studies in locally advanced or metastatic penile cancer.
阴茎癌较为罕见，绝大多数为鳞状细胞癌，30%至40%的病例中可检测到人乳头瘤病毒（HPV）。在局部晚期或转移阶段，一线治疗依赖基于铂类和紫杉烷的多药化疗。晚期或转移性阴茎癌的预后仍然很差，总生存期为13.9至17.1个月。一线治疗后，指南推荐了各种化疗方案或靶向抗表皮生长因子受体（EGFR）治疗，但这些治疗的效果以及证据水平都很有限。对阴茎癌致癌途径的深入了解以及程序性死亡受体配体1（PD-L1）的频繁表达为制定新策略提供了理论依据。本文综述了局部晚期或转移性阴茎癌的数据、指南及正在进行的研究。
